Trim 10-15% into $91.50-$92.50 bid zone; structural stop at $88.30-$88.70 SMA cluster (not trader's $87.80 breakeven)
The structural pillars remain intact (47+ consecutive dividend raises, 1.4x FCF coverage, 0.57 defensive beta, accelerating CV/PFA/robotics exposure), supporting Underweight rather than full Underweight or Sell. However, the $94 trim trigger has been tested three times without breaking, MACD has rolled over with widening negative histogram, and repeated Hold ratings produced cumulative -1.2% alpha bleed. The binding 9/17 lesson is that time-bounded reassessment must trigger hard sizing action rather than another patience extension. Stop placement refines the trader's breakeven $87.80 to the structurally meaningful $88.30-$88.70 SMA cluster.
| Position | Action |
|---|---|
| Now | Trim 10-15% of MDT exposure into the $91.50-$92.50 bid zone |
| Core position | Retain 85-90% core position anchored by structural stop at $88.30-$88.70 |
| On escalation above $94.70 with >12M volume + MACD positive re-cross | Escalate to Overweight, add back trimmed portion |
| On flush to $85-$87 with reversal confirmation | Reserve dry powder for potential accumulation |
Medtronic offers an asymmetric risk/reward at 14.4x forward earnings with accelerating growth, competitive share gains, and a multiple-expanding carve-out — a quality compounder priced like a value stock.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | $88.32 | bullish |
| close_50_sma | $88.70 | bullish |
| close_10_ema | $92.49 | bearish |
| rsi | 53.37 | neutral |
| macd_line | 1.03 | bearish |
| macd_signal | 1.29 | bearish |
| macd_histogram | -0.26 | bearish |
| bollinger_middle | 92.23 | neutral |
| bollinger_upper | 94.45 | neutral |
| bollinger_lower | 90.01 | neutral |
| vwma | 92.57 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Flush to $85-$87 on structural SMA pullback with reversal confirmation
Then: Reserve dry powder for accumulation
Forward P/E of 14.4x is cheap relative to peers and the broad market, not expensive as the bear claims.
↩ rebuts: “The bear argues MDT looks expensive on a trailing P/E of 22.7x”
EV: +5.4% to +8.5% (Targets: $97 → $100+ from $92 entry over 3–6 months) · concedes: Bear anchors on historical 3.6% revenue growth from FY24–FY25; MiniMed separation carries execution risk; Trailing P/E of 22.7x is elevated (but addressed by the 14.4x forward multiple); $53B goodwill/intangibles balance is high from decades of acquisitions
Medtronic is a mature mega-cap device company with a 4-5% structural growth rate, a 22.7x trailing P/E that prices in perfection, deteriorating buyback support, a triple-top technical pattern failing at $94, and a planned spin-off that strips out its highest-growth diabetes franchise—creating a multiple compression story at exactly the wrong macro moment with 10Y yields at 5% and zero Fed cut probability.
EV: $88.50 (50/200 SMA cluster) → $84.97 (March swing low / lower Bollinger band) → $80 (re-test of post-spin-off narrative compression) · concedes: Q1 FY27 revenue acceleration (+13.8%) is real, though the tax benefit inflated the EPS component; MiniMed separation does unlock CGM-focused investor base if execution is clean; Hugo is gaining ground incrementally as distant #2 in robotic surgery; Dividend at 3.1% yield remains a floor for institutional holders
→ vs conservative: The wait-for-breakout thesis ($94.50 confirmation) is the classic retail mistake of buying after the move; accumulation should happen now in the $91-$92 zone ahead of the November Q2 FY27 print
→ vs conservative: The 68% buyback cut framing is intellectually lazy; the $1.16B Q1 FY27 M&A deployment represents offensive capital allocation toward high-growth initiatives (MiniMed separation, Recor/Barghout RDN, bolt-on acquisitions), not capital discipline weakness
→ vs conservative: The MACD rolling over argument is the weakest technical analysis in the report; a 0.26 histogram on a $92 stock is noise, and momentum oscillators flattening during Bollinger band compression is expected behavior, not a sell signal
→ vs neutral: Reddit silence is a positioning opportunity, not a risk factor; absence of retail froth means institutional accumulation is happening cleanly without speculative unwind risk
→ vs neutral: The conservative and neutral camps are prioritizing capital preservation over return optimization by holding at these levels when the risk-reward heavily favors the upside
| neutral |
| atr | 2.13 | neutral |
Support: 90.01 · 88.32 · 84.97 | Resistance: 94.45 · 97 · 98
Technical posture is neutral-to-cautiously-bullish. Long-term trend is confirmed bullish (price above both 50 SMA and 200 SMA), but short-term trend shows weakening with price below the 10 EMA and lower highs forming. RSI at 53.37 is neutral with no extremes. MACD has issued a bearish crossover with histogram widening negative, indicating fading momentum. Bollinger Bands are tightening (4.8% width) around the midline at $92.23, creating a coiled volatility setup. Resistance sits at $94.17–94.45 (triple-tested ceiling) and $97–98; key support at $90.01 (BOLL lower), $88.32–88.70 (50/200 SMA cluster), and $84.97 (March 2026 swing low). VWMA at $92.57 is only $0.44 above close, confirming price authenticity, but high volume on a red day signals mild bearish short-term volume divergence. ATR of 2.13 (~2.3% of price) reflects low-volatility environment. Base case expects continued consolidation between $90 and $94.50, with directional breakout likely within 5–10 sessions.
Market Cap
$117.85B
P/E (TTM)
22.69
Forward P/E
14.38
Forward EPS
$6.41
PEG Ratio
1.66
Price/Book
2.35
Dividend Yield
3.10%
Beta
0.574
52-Week Range
$73.31 – $106.33
50-day MA
$88.50
200-day MA
$89.32
FY2026 Revenue
$36.36B
FY2025 Revenue
$33.54B
FY2024 Revenue
$32.36B
FY2023 Revenue
$31.23B
FY2026 Net Income
$4.80B
FY2025 Net Income
$4.66B
FY2026 Diluted EPS
$3.73
FY2025 Diluted EPS
$3.61
FY2023 Diluted EPS
$2.82
Gross Margin (TTM)
~65.3%
Operating Margin (TTM)
19.3%
EBITDA Margin (TTM)
27.7%
Net Profit Margin (TTM)
13.9%
ROE
10.6%
ROA
5.1%
Q1 FY27 Revenue
$9.76B
Q1 FY27 Diluted EPS
$1.14
Q1 FY27 Net Income
$1.47B
Q1 FY27 Operating Margin
~18.8%
Q1 FY27 FCF
$1.29B
Q1 FY27 Effective Tax Rate
16.3%
Total Assets
$93.31B
Total Equity
$50.85B
Tangible Book Value
-$3.19B
Goodwill
$43.19B
Total Debt
$28.15B
Net Debt
$26.41B
Net Debt/EBITDA
~2.5x
Cash + ST Investments
$8.82B
Current Ratio
2.07
Debt/Equity
55.4%
Inventory
$6.22B
Receivables
$6.36B
Working Capital
$12.59B
Share Count
1.280B
Operating Cash Flow (FY2026)
$7.33B
FCF (FY2026)
$5.43B
FCF/Share (FY2026)
>$4.20
CapEx (FY2026)
$1.90B
Acquisitions (FY2026)
$0.41B
Dividends Paid (FY2026)
$3.64B
Buybacks (FY2026)
$1.04B
Capital Return (FY2026)
~$4.7B
Payout Ratio
~75%
Goodwill/Assets
~46%
Strengths
Concerns
Medtronic is a mega-cap ($117.85B) medical device bellwether with accelerating top-line momentum (+8.4% FY2026 revenue growth, +13.8% YoY in Q1 FY27 to $9.76B) and remarkably stable ~65% gross margins, though the trailing P/E of 22.7x is rich relative to the 14.38x forward multiple. The company generates robust FCF ($5.43B in FY2026) supporting a 3.10% dividend yield and ~87% capital return rate, while the balance sheet carries manageable leverage (net debt/EBITDA ~2.5x) against a $43.19B goodwill base. Key risks include the premium valuation, $53B in goodwill/intangibles, FX headwinds, regulatory exposure, and a high ~75% payout ratio limiting reinvestment flexibility, making this best suited as a defensive core long-term holding rather than a tactical trade.
Macro: 10-Year Treasury hovering near 5% (modest duration pressure on multiples); Polymarket pricing 95% probability of zero Fed cuts in 2026 (sticky rates regime consensus); 8% probability of US recession by end-2026 (low base case supportive of elective procedure volumes); defensive positioning favoring dividend aristocrats; CMS TAVR coverage expansion bullish for structural-heart revenue pools.